CCL19 and Cowden syndrome 1: Other substances, proinflammatory chemokines CCL19 and CCL13, had significantly lower concentrations in the plasma samples of the patients at the time of remission achievement with CS treatment than those in remission after termination of CS treatment, suggesting their potential role as biomarkers of disease activity, obviously influenced by CS treatment.